ES2660249T3 - Compuestos de tipo triazolona y sus usos - Google Patents

Compuestos de tipo triazolona y sus usos Download PDF

Info

Publication number
ES2660249T3
ES2660249T3 ES13863783T ES13863783T ES2660249T3 ES 2660249 T3 ES2660249 T3 ES 2660249T3 ES 13863783 T ES13863783 T ES 13863783T ES 13863783 T ES13863783 T ES 13863783T ES 2660249 T3 ES2660249 T3 ES 2660249T3
Authority
ES
Spain
Prior art keywords
alkyl
cycloalkyl
halogen
heteroaromatic ring
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13863783T
Other languages
English (en)
Inventor
Nicholas Simon Stock
Austin Chih-Yu Chen
Yalda Mostofi Bravo
Jason Duarte Jacintho
Jill Melissa Baccei
Brian Andrew Stearns
Ryan Christopher Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inception 2 Inc
Original Assignee
Inception 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inception 2 Inc filed Critical Inception 2 Inc
Application granted granted Critical
Publication of ES2660249T3 publication Critical patent/ES2660249T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula I**Fórmula** o una sal farmacéuticamente aceptable de este donde: A1 es un anillo fenilo o un anillo heteroaromático de 6 miembros que tiene 1, 2 o 3 N en el anillo heteroaromático; A2 se selecciona entre A2a o A2b**Fórmula** donde A2a es un anillo fenilo o un anillo heteroaromático de 6 miembros que tiene 1, 2 o 3 N en el anillo heteroaromático, y A2b es un anillo heteroaromático de 5 miembros que tiene 1, 2 o 3 heteroátomos seleccionados de manera independiente entre O, S y N; X se selecciona a partir del grupo constituido por -(CH2)2-, -(CH2)3-, -(CH2)4-, y -(CH2)m-O-(CH2)n-, mono- o disustituido de manera opcional con halógeno, donde m y n son de manera independiente 0, 1, 2, 3 o 4, siempre que m+n sea 2, 3 o 4; Y es O; R1 y R2 se seleccionan cada uno de manera independiente a partir del grupo constituido por: (a) hidrógeno, (b) halógeno, (c) CN, (d) CF3, (e) -alquilo C1-6, (f) -(alquilo C1-6)-C(>=O)OH, (g) -O-(R7), (h) -S(>=O)oR7, (i) -N(R7)(R8), (j) -N(R7)-C(>=O)-(R8), (k) -N(R7)-C(>=O)-O-(R8), (l) -N(R7)S(>=O)2(R8), (m) -(cicloalquilo C3-6), (n) -C(>=O)(R7), (o) arilo, (p) heteroarilo, (q) -OC(>=O)N(R7)(R8), (r) -S(>=O)2N(R7)(R8), (s) -C(>=O)N(R7)(R8) y (t) -C(R7)(R8)OH, donde la porción alquilo de las opciones (e) y (f), y la porción cicloalquilo de la opción (m) están sustituidas de manera opcional con halógeno, y donde el arilo de la opción (o) y el heteroarilo de la opción (p) están mono- o disustituidos de manera opcional con sustituyentes seleccionados entre halógeno, nitro, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, cicloalquilo C3-6, cicloalcoxi C3-6, -NH(alquilo C1-6), -NH(cicloalquilo C3-6), -N(alquilo C1-6)2, -N(cicloalquilo C3-6)2, -S(>=O)o(alquilo C1-6), - S(>=O)o(cicloalquilo C3-6) y CN; R3 se selecciona a partir del grupo constituido por: (a) hidrógeno, (b) halógeno, (c) CN, (d) CF3, (e) -alquilo C1-6, (f) -(alquilo C1-6)-C(>=O)OH, (g) -O-(R7), (h) -S(>=O)oR7 (i) -N(R7)(R8), (j) -N(R7)-C(>=O)-(R8), (k) -N(R7)-C(>=O)-O-(R8), (l) -N(R7)S(>=O)2(R8), (m) -(cicloalquilo C3-6), (n) -C(>=O)(R7), (o) arilo, (p) heteroarilo, (q) -OC(>=O)N(R7)(R8), (r) -S(>=O)2N(R7)(R8), (s) -C(>=O)N(R7)(R8), (t) -C(R7)(R8)OH, (u) -NHC(>=O)-N(R7)(R8), (v) -(cicloalquil C3-6)-COOH, (w) heterociclo y (x) -(alquil C1-6)C(>=O)-N(R7)(R8), donde la porción alquilo de las opciones (e), (f) y (x), y la porción cicloalquilo de las opciones (m) y (v) están sustituidas de manera opcional con halógeno o hidroxilo, y
ES13863783T 2012-12-20 2013-12-10 Compuestos de tipo triazolona y sus usos Active ES2660249T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739906P 2012-12-20 2012-12-20
PCT/US2013/074197 WO2014099503A1 (en) 2012-12-20 2013-12-10 Triazolone compounds and uses thereof

Publications (1)

Publication Number Publication Date
ES2660249T3 true ES2660249T3 (es) 2018-03-21

Family

ID=50979036

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13863783T Active ES2660249T3 (es) 2012-12-20 2013-12-10 Compuestos de tipo triazolona y sus usos

Country Status (17)

Country Link
US (4) US9676754B2 (es)
EP (1) EP2935228B9 (es)
JP (1) JP6404230B2 (es)
KR (1) KR102300675B1 (es)
CN (1) CN104918922B (es)
AU (1) AU2013363398B2 (es)
BR (1) BR112015013350B1 (es)
CA (1) CA2894281C (es)
DK (1) DK2935228T3 (es)
EA (1) EA027986B9 (es)
ES (1) ES2660249T3 (es)
IL (1) IL239372B (es)
MX (1) MX376108B (es)
NO (1) NO3003327T3 (es)
PE (1) PE20151521A1 (es)
SG (1) SG11201504622PA (es)
WO (1) WO2014099503A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) * 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
WO2022052982A1 (zh) * 2020-09-14 2022-03-17 昭明泽康（北京）生物医药科技有限公司 PPARα（过氧化物酶体增殖物激活受体α）配体在制备药物中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
TW202428262A (zh) * 2022-11-09 2024-07-16 美商坦帕斯醫療公司 三唑酮化合物及其用途
WO2025235527A1 (en) 2024-05-08 2025-11-13 Tempest Therapeutics, Inc. Crystalline forms of a ppar alpha antagonist

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE160447C (es)
DK160611C (da) 1979-09-04 1991-09-16 Bristol Myers Squibb Co Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider
US4487773A (en) 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
IN158869B (es) 1981-03-18 1987-02-07 Ici Plc
DD160447A1 (de) 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
DE3267110D1 (de) 1981-05-18 1985-12-05 Ici Plc Amidine derivatives
DE3238590A1 (de) 1982-10-19 1984-04-19 VEB Fahlberg-List Chemische und pharmazeutische Fabriken, DDR 3013 Magdeburg Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
NL8204109A (nl) 1982-10-25 1984-05-16 Fahlberg List Veb Herbicide middelen, die 1.2.4-triazolinon-(5)-verbindingen bevatten.
BE894856A (fr) 1982-10-28 1983-02-14 Fahlberg List Veb Compositions herbicides a base d'un derive de la 1,2,4-triazolinone-(5)
FR2535168B1 (fr) 1982-10-29 1985-08-09 Fahlberg List Veb Agents herbicides a base de 1, 2, 4-triazolinone 5
JPS60215675A (ja) 1984-04-09 1985-10-29 Nippon Nohyaku Co Ltd オキサジアゾリノン誘導体及びトリアゾリノン誘導体並びにその製造方法並びに昆虫成長制御剤
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE3934081A1 (de) 1989-10-12 1991-04-18 Bayer Ag Sulfonylaminocarbonyltriazolinone
CA2073005C (en) 1990-09-06 1998-11-10 Alan Stobie Antimuscarinic bronchodilators
JP2772875B2 (ja) 1991-05-14 1998-07-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法及び写真用漂白定着組成物
SG47949A1 (en) 1991-10-30 1998-04-17 Astra Ab 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
WO1993021181A1 (en) 1992-04-15 1993-10-28 Merck Sharp & Dohme Limited Azacyclic compounds
DE4224929A1 (de) 1992-07-28 1994-02-03 Bayer Ag Heterocyclyltriazolinone
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
IT1256387B (it) 1992-11-13 1995-12-04 Acraf Procedimento per preparare triazoloni
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE4343595A1 (de) 1993-12-21 1995-06-22 Bayer Ag Verfahren zur Herstellung von Sulfonylaminocarbonyltriazolinonen
US5550118A (en) 1994-01-31 1996-08-27 Eli Lilly And Company Polyhydronorharman synthase inhibitors
DE4404848A1 (de) 1994-02-16 1995-08-17 Hoechst Ag Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
JPH08157473A (ja) 1994-10-06 1996-06-18 Nissan Chem Ind Ltd ピラゾール系チアゾリジン類
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
IN183333B (es) 1995-03-15 1999-11-20 Indian Drugs & Pharma
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
DE19521162A1 (de) 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
GB9513121D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
DE19601189A1 (de) 1996-01-15 1997-07-17 Degussa Verfahren zur Herstellung von 1,2,4-Triazolin-3(2H)-onen
EP0784053A1 (de) 1996-01-15 1997-07-16 Degussa Aktiengesellschaft Verfahren zur Herstellung von Triazolinonherbiziden
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE69736390T2 (de) 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1999003835A1 (en) 1997-07-18 1999-01-28 Nippon Kayaku Kabushiki Kaisha Aromatic ketone derivatives and uses thereof
EP1049693A1 (en) 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
CA2333964A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
CN1295561A (zh) 1998-06-03 2001-05-16 Gpinil控股公司 N－杂环羧酸或羧酸等排物的n－结合氨磺酰
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
CA2336152A1 (en) 1998-08-14 2000-02-24 Gpi Nil Holdings, Inc. Ureas and carbamates of n-heterocyclic carboxylic acids and isosteres for vision and memory disorders
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
DE19955662B4 (de) 1999-11-19 2011-03-31 Arysta LifeScience North America, Herbizide auf Basis von Carbamoyltriazolinon
EP1110958A1 (en) 1999-12-20 2001-06-27 Ucb, S.A. Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU6594401A (en) 2000-05-24 2001-12-03 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
CA2469821C (en) 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
ATE403426T1 (de) 2002-02-07 2008-08-15 Univ Missouri Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
EP1513829A2 (en) 2002-06-14 2005-03-16 Syngenta Participations AG Nicotinoyl derivatives as herbicidal compounds
WO2004032846A2 (en) 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
WO2004032879A2 (en) 2002-10-11 2004-04-22 Cytokinetics, Inc. Compounds, compositions, and methods
PL375889A1 (en) 2002-10-11 2005-12-12 Cytokinetics, Inc. Compounds for treating cellular proliferative diseases, compositions containing them and their application
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CA2521396A1 (en) 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
DE602004025220D1 (de) 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077178A2 (en) 2004-02-16 2005-08-25 Syngenta Participations Ag Herbicidal composition
EP1720860A1 (en) 2004-02-18 2006-11-15 AstraZeneca AB Triazole compounds and their use as metabotropic glutamate receptor antagonists
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2006010545A1 (en) 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
CN1315810C (zh) 2004-08-30 2007-05-16 北京理工大学 哌嗪桥联他克林双体衍生物及其合成方法
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
DE602006014502D1 (de) 2005-01-14 2010-07-08 Janssen Pharmaceutica Nv Pyrazolopyrimidine als zellzyklus-kinasehemmer
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
PE20061041A1 (es) 2005-01-28 2006-10-12 Lilly Co Eli Formulaciones y regimen de dosificacion para moduladores alfa de ppar
JP5289043B2 (ja) 2005-04-12 2013-09-11 ヴィコール・ファルマ・アーベー 新規な三環系アンジオテンシンｉｉアゴニスト
CN101213729B (zh) 2005-04-28 2013-06-12 株式会社电装 交流电动机
DE102005025992A1 (de) 2005-06-07 2007-01-11 Lanxess Deutschland Gmbh Verfahren zur Herstellung von substituierten Azolen
WO2007019397A2 (en) 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102006003444A1 (de) 2006-01-25 2007-07-26 Lanxess Deutschland Gmbh Verfahren zur Herstellung von iodierten Azolen
GB2435828A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted phenyl-piperazine compounds for treatment of food related disorders
GB2435829A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake
GB2435827A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
BRPI0709110A2 (pt) 2006-03-23 2011-06-28 Prolysis Ltd agentes antibacterianos
CA2647423C (en) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Triazolone derivative
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
CA2653222A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006032164A1 (de) 2006-07-12 2008-01-24 Bayer Cropscience Ag Substituierte Furyl-sulfonylamino(thio)carbonyl-triazolin(thi)one
US7994321B2 (en) 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
CN101535303B (zh) 2006-08-15 2012-07-18 诺瓦提斯公司 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物
CA2678846A1 (en) 2007-02-23 2008-08-28 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
JP2010524861A (ja) 2007-04-20 2010-07-22 メルク フロスト カナダ リミテツド ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤としての新規な複素環式芳香族化合物
WO2009017863A2 (en) 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
ES2617305T3 (es) 2007-07-17 2017-06-16 Acea Biosciences, Inc. Compuestos heterocíclicos y usos como agentes anticancerosos
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US8222254B2 (en) 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
NZ585704A (en) 2007-12-10 2012-08-31 7Tm Pharma As Modulators of cannabinoid receptor CB1 for treating obesity
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
SI2291080T1 (sl) 2008-05-14 2015-11-30 The Scripps Research Institute Novi modulatorji sfingosinskih fosfatnih receptorjev
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US7943796B2 (en) * 2008-07-31 2011-05-17 Chevron Oronise Company LLC Lubricating oil additive and lubricating oil composition containing same
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
JP2011231015A (ja) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
NZ592603A (en) 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
WO2010139966A1 (en) 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011058478A1 (en) 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
KR101169359B1 (ko) 2010-01-29 2012-07-30 주식회사 레고켐 바이오사이언스 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
ES2509951T3 (es) 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
EP2371823A1 (de) 2010-04-01 2011-10-05 Bayer CropScience AG Cyclopropyl-substituierte Phenylsulfonylamino(thio)carbonyltriazolinone, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2012027482A2 (en) 2010-08-24 2012-03-01 Georgetown University Compounds, compositions and methods related to ppar antagonists
WO2012037299A2 (en) * 2010-09-17 2012-03-22 Glaxosmithkline Llc Fatty acid synthase inhibitors
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof

Also Published As

Publication number Publication date
SG11201504622PA (en) 2015-07-30
CN104918922A (zh) 2015-09-16
NO3003327T3 (es) 2018-01-06
US20240041837A1 (en) 2024-02-08
EA027986B9 (ru) 2018-01-31
BR112015013350B1 (pt) 2022-04-05
EA201590909A1 (ru) 2015-12-30
AU2013363398B2 (en) 2017-06-01
IL239372A0 (en) 2015-07-30
EA027986B1 (ru) 2017-09-29
US20200138790A1 (en) 2020-05-07
DK2935228T3 (en) 2017-10-30
CN104918922B (zh) 2017-04-26
EP2935228B1 (en) 2017-08-02
US9676754B2 (en) 2017-06-13
KR102300675B1 (ko) 2021-09-13
MX2015007433A (es) 2015-12-07
US20170239223A1 (en) 2017-08-24
BR112015013350A2 (pt) 2017-07-11
JP6404230B2 (ja) 2018-10-10
EP2935228B9 (en) 2017-12-06
CA2894281C (en) 2021-04-20
EP2935228A1 (en) 2015-10-28
US10568871B2 (en) 2020-02-25
CA2894281A1 (en) 2014-06-26
IL239372B (en) 2018-08-30
MX376108B (es) 2025-03-07
EP2935228A4 (en) 2016-05-04
US20150344446A1 (en) 2015-12-03
KR20150099537A (ko) 2015-08-31
AU2013363398A1 (en) 2015-07-23
PE20151521A1 (es) 2015-11-25
JP2016508132A (ja) 2016-03-17
US11666557B2 (en) 2023-06-06
HK1212680A1 (zh) 2016-06-17
WO2014099503A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
ES2660249T3 (es) Compuestos de tipo triazolona y sus usos
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR111682A1 (es) Derivados de imidazopirimidina con sustituyentes fenilo y piridilo que contienen azufre
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR098912A1 (es) Inhibidores de syk
AR092684A1 (es) Compuestos de sulfonamida sustituidos
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR091246A1 (es) Procesos para producir 2-(piridin-3-il)tiazoles
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR090328A1 (es) Pirrolidina-2-carboxamidas sustituidas
AR100312A1 (es) Compuestos de diaminotriazina
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR093767A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR093515A1 (es) Triazolopirazinas
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
AR095421A1 (es) Moduladores de p2x7
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR096613A1 (es) Moduladores de la acetil-coa carboxilasa
AR099789A1 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR095349A1 (es) Compuesto y composición farmacéuticamente aceptable, útil para tratar enfermedad o trastorno tal como la enfermedad de huntington u otra patología neurodegenerativa
AR098818A1 (es) Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos